Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · OCULAR THERAPEUTIX, INC (OCUL)

Ocular Therapeutix names Jason Robins CFO; stockholders approve 10M-share plan increase

Neutral Impact 3 of 5 leadership Written later

At its June 10, 2026 annual meeting, Ocular Therapeutix stockholders approved Amendment No. 5, which adds 10,000,000 shares to the 2021 Stock Incentive Plan, and re-elected two Class III directors. The Board also formally appointed Jason Robins, who had been interim CFO since January 20, 2026, as Chief Financial Officer, with a higher base salary and equity grants.

Key points

  • Stockholders approved Amendment No. 5, adding 10,000,000 shares to the 2021 Stock Incentive Plan, with 150,723,228 votes for and 5,688,862 against.
  • Jason Robins was appointed CFO on June 10, 2026; his base salary rises to $535,100 on July 1, 2026, with a bonus target of 45% of base salary.
  • Robins received a stock option for up to 14,024 shares and a restricted stock unit award for 15,441 shares, both effective June 10, 2026.
  • Pravin U. Dugel, M.D. and Merilee Raines were elected Class III directors, and PricewaterhouseCoopers LLP was ratified as auditor for fiscal 2026.

The filing

CompanyOCULAR THERAPEUTIX, INC (OCUL)
Form8-K, current report
Filed with the SECJun 12, 2026, 4:23 PM ET
Accession number0001104659-26-073496

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.